Annual Report 2005 - Boehringer Ingelheim

health market. With
sales of almost 30 % in
the market, Italy made a
very substantial contri-
bution to the perform-
ance of antistax® in
2005.
mucoangin® – our sore throat brand – achieved
satisfactory growth in the major markets Germany
and Mexico. New product launches were made in
Denmark and Sweden.
mucosolvan® – the world’s
leading cough expectorant –
strengthened its position with
good growth of 14 %, compared
with 2004. New marketing
campaigns were initiated in
Mexico, Brazil and Germany
during the year.
bisolvon® – the cough remedy
– consolidated its position as one of the leading
brands in the world OTC
expectorant market. In
2005, it successfully sus-
tained its strong position
in many markets, particu-
larly in South America
and Europe, achieving
double-digit growth.
pharmaton® – our umbrella brand for the
improvement and maintenance of vitality and
well-being – performed well in 2005, with strong
growth in the key markets in Latin America –
Mexico, Brazil and Argentina.
IMS figures put pharmaton®
as world No. 2 in its category.
In 2005, development of a vali-
dated international brand plat-
form was started, with imple-
mentation expected to start in
2006. This will help capitalise on the strong brand
image/market position that pharmaton® com-
mands in many markets. pharmaton® kiddi
(children’s supplement) produced strong growth
in Mexico in 2005, boosted by the launch of
galenic line extensions in late 2004.
Development by region
Europe
In 2005, the region reported sales growth as of
14 % compared to the previous year, as a result of
a favourable seasonal demand for cough & cold
brands combined with several line extension
launches, switches and healthy, above-market
growth. Activities in 2005 were intensively
focused on our international brands. Germany,
Spain, Italy and Russia, our major markets in
Europe, were the prime drivers of the positive
development.
Americas
The year 2005 was a very positive one for the
CHC business in the Americas Region, which
achieved growth of 19 % against previous year.
The main growth driver was Mexico.
Asia, Australasia, Africa (AAA)
SSP Co. Ltd. – the No. 3 OTC company in Japan,
whose major shareholder is Nippon Boehringer
Ingelheim Co. Ltd. – strengthened its position in a
highly competitive market environment. The AAA
Region, excluding Japan, achieved strong growth
of +16 % against the previous year. Our interna-
tional core brands pharmaton®, bisolvon® and
dulcolax® showed overall sales growth of 86 %.
Consumer Health Care
1